LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting
LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract Number：e16102
Abstract Title：Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1]. Approximately 50% of the advanced GC patients will develop peritoneal metastasis after radical resection, along with malignant ascites in most cases. Furthermore, peritoneal metastasis is associated with poor prognosis and quality of life compared with metastasis to other organs [2]. Peritoneal metastasis is treated with systemic therapies. The estimated survival period for the patients who fail to respond to third-line therapy is limited to only 2.3-2.4 months according to multiple RCTs.
In our study, 9 GC patients with peritoneal metastasis (33% had failed third-line therapy) were treated with Catumaxomab, the median overall survival was 3.4 months, with remarkable ascites regression. Catumaxomab as an T cell engaging immunotherapy has showed promising early efficacy signals.
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer (NCT04222114) and non-muscle invasive bladder cancer (NCT04799847).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. For more information, please visit www.lintonpharm.com
Reference
1. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/
2. Jennifer L.L. & Travis E.G. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018 October 15; 10(10): 282-289.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005174/en/
Contact information
Media Contacts:
Mia He
LintonPharm
jingyi.he@lintonpharm.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Revolutionize Brand Engagement: MSquared Puts Interoperability Center Stage in MLB’s Virtual Ballpark!26.9.2024 22:48:00 CEST | Press Release
Solving the Interoperability Challenge MSquared’s demonstration is the first major showcase of how it has solved the technical challenges of metaverse interoperability. The integration of the Metaverse Markup Language (MML) lies at the heart of this success, offering a revolutionary way to define interactive 3D content that can seamlessly run across different virtual spaces and engines. Additionally, M² has developed a secure digital rights management and moderation system that allows IP owners and consumers to have appropriate protections as content moves freely between worlds. “MSquared has systematically overcome the challenges of interoperability - from ownership to standardized visualizations and secure asset storage,” said Rob Whitehead, Chief Product Officer of Improbable. “Our technology safeguards intellectual property and brand integrity across diverse virtual environments, ensuring seamless and secure experiences.” Elevate Your Brand in the Metaverse This milestone event in
Grid Dynamics Expands Global Footprint with JUXT Acquisition, Strengthening Expertise in Banking and Financial Services26.9.2024 22:05:00 CEST | Press Release
Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and digital engagement services, today announces its acquisition of JUXT, a UK-based provider of software engineering services specializing in data-intensive information systems for banking and other financial institutions, with a particular focus on risk platforms, structured notes, equity derivatives, and financial reporting. With this acquisition, Grid Dynamics adds significant expertise and capabilities to better serve enterprise clients in the financial services industry. Founded in 2013, JUXT is known for delivering complex end-to-end solutions, from design and user experience, to deep functionality and ongoing managed services. Their specializations in mission-critical platforms and products for leading banks and financial institutions make them a strategically important addition to Grid Dynamics, especially as global demand for reliable
BM3EAC Corp. 2024 Semi-Annual Report26.9.2024 20:58:00 CEST | Press Release
BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2024 to 30 June 2024. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announ
UCC Holding Ranked 42 nd in ENR’s Top International Contractors26.9.2024 20:32:00 CEST | Press Release
Urbacon Holding, a leader in energy, concessions, and construction, announced its ranking as the 42nd top international contractor for 2024, according to Engineering News-Record (ENR). The company celebrated this achievement during the ConteQ Expo 2024 in Qatar, where it participated as the event's official sponsor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240926450701/en/ UCC Holding Ranked 42nd in ENR’s Top International Contractors (Photo: AETOSWire) The event brought together UCC Holding’s Board of Directors and senior management, who emphasized the company’s ongoing efforts to integrate advanced construction technologies into its operations. During the expo, UCC Holding introduced three innovative construction methods: 3D construction printing, concrete modular construction, and steel structure modular construction. These technologies are already being incorporated into UCC’s future projects, including a series of
Sinopec Awarded Best Environmental Protection Case at First Sino-European Corporate ESG Best Practice Conference26.9.2024 19:06:00 CEST | Press Release
The ESG case from China’s Sinopec, titled “Empowering Green Development, Co-Creating a Zero-Carbon Future,” stood out from dozens of entries and was awarded the Best Case in the Environmental Protection category at the first Sino-European Corporate ESG Best Practice Conference held in Frankfurt, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240926903754/en/ An ESG case from China’s Sinopec was awarded the Best Case in the Environmental Protection category at the first Sino-European Corporate ESG Best Practice Conference held in Frankfurt, Germany. (Photo: Business Wire) Walter Döring, Chairman of German World Market Leaders Association, on behalf of the event's organizing committee, announced the results. He stated, “Sinopec has demonstrated exceptional practical value in environmental protection. Through its comprehensive environmental management system and innovative technological means, as well as the use of cle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom